Evidence map›Paper›PMID 34735984›Full record

ReviewCurrent opinion in biotechnology2022

Virus-like particles against infectious disease and cancer: guidance for the nano-architect.

Rory A Hills, Mark Howarth

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. De Novo Design of Proteins for Autocatalytic Isopeptide Bond Formation.Journal of the American Chemical Society · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Virus-like Particles for TEM Regulation and Antitumor Therapy.Journal of functional biomaterials · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rory A HillsDepartment of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK.
Mark HowarthDepartment of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK. Electronic address: mark.howarth@bioch.ox.ac.uk.
University of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Virus-like particles (VLPs) can play important roles in prevention and therapy for infectious diseases and cancer. Here we describe recent advances in rational construction of VLP assemblies, as well as new approaches to enhance long-lasting antibody and CD8

Indexed as

Communicable DiseasesCOVID-19NeoplasmsVaccines, Virus-Like ParticleAdjuvants, ImmunologicHumansSARS-CoV-2Adjuvants, ImmunologicVaccines, Virus-Like Particle

Identifiers

PMID34735984
PMCPMC8555979
OpenAlexW3208510654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.